Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Hyperfibrinolysis
Interventions
PROCEDURE

Blood sampling (pregnant)

"5.4 ml of venous blood will be taken during the delivery or the caesarian procedure, in addition to the standard of care blood sampling.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."

PROCEDURE

Blood sampling (non pregnant)

"5.4 ml of venous blood will be taken.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."

Trial Locations (1)

1020

CHU Brugmann, Brussels

All Listed Sponsors
lead

Brugmann University Hospital

OTHER

NCT02579941 - Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term. | Biotech Hunter | Biotech Hunter